ReviewThe American journal of case reports2025
Sodium Valproate-Associated Thrombocytopenia in Antiepileptic Drug Polypharmacy: A Case Report and Review of the Literature.
Review in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Drug-induced thrombocytopenia (DITP) is a potentially life-threatening adverse drug reaction, representing approximately 20% to 25% of acquired thrombocytopenia cases. Sodium valproate (VPA) and levetiracetam are widely used antiepileptic drugs; reported incidences of VPA-associated thrombocytopenia range from 5% to 32%, depending on serum concentrations. Although both agents are frequently combined in the management of refractory epilepsy, limited information is available regarding their synergistic hematological risks. CASE REPORT We encountered a case of DITP in a 31-year-old man with an epileptic mental disorder who was receiving VPA and levetiracetam in combination. The patient had previously received either VPA or levetiracetam as monotherapy without thrombocytopenia onset. However, after initiation of combination therapy, the patient developed progressive thrombocytopenia, with a nadir platelet count of 47×10⁹/L. Laboratory testing revealed a serum VPA concentration of 112.4 μg/mL, exceeding the therapeutic range (50-100 μg/mL). After VPA discontinuation, the platelet count gradually recovered to 93×10⁹/L, approaching normal levels. CONCLUSIONS This case highlights a potential pharmacokinetic interaction between levetiracetam and VPA, suggesting that levetiracetam can influence VPA metabolism. It underscores the importance of close therapeutic drug monitoring of VPA concentrations during combination therapy and emphasizes the need for further investigation into metabolic interactions between novel and conventional antiepileptic agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.